-transparent.png){kind=logo}
We determined changes in serum concentrations of thyroid hormones during carbamazepine (CBZ) therapy during a 5-year prospective follow-up study of 20 patients with newly diagnosed epilepsy. In addition, we evaluated the effects of replacing CBZ with oxcarbazepine (OCBZ) in 12 male patients with epilepsy in a 6-month prospective follow-up study. Circulating thyroxine and free thyroxine levels decreased after 2-month CBZ treatment and remained at a low level during the 5-year follow-up. There were no associated changes in serum thyrotropin (TSH) concentrations. When CBZ was replaced by OCBZ, the function of the liver's P450 enzyme system normalized, as shown by an increase in antipyrineT1/2, and a decrease in antipyrineCL. Serum total and free thyroxine levels increased, and thereafter serum TSH levels decreased. Indexes of diastolic heart function improved concomitantly, which may reflect subclinical hypothyroidism at the cellular level during CBZ treatment. We conclude that normal thyroid function can be restored in patients with epilepsy by replacing CBZ with OCBZ.
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
December 2007,
Pediatrics international : official journal of the Japan Pediatric Society,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
July 2001,
Epilepsia,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
March 2004,
Epilepsia,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
January 1994,
Epilepsia,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
October 1992,
Therapeutic drug monitoring,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
December 2005,
Neurology,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
August 2016,
European journal of clinical pharmacology,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
January 1995,
European journal of clinical pharmacology,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
December 2002,
Neuropediatrics,
J I Isojärvi, and
K E Airaksinen, and
J N Mustonen, and
A J Pakarinen, and
A Rautio, and
O Pelkonen, and
V V Myllylä
July 1994,
Biological psychiatry,
